FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152667734> ?p ?o ?g. }

• W2152667734 abstract "You have accessJournal of UrologyProstate Cancer: Basic Research V1 Apr 2014MP52-08 TARGETING IGFBP-2 AND IGFBP-5 IN CASTRATION AND ENZALUTAMIDE RESISTANT PROSTATE CANCER Joseph Ischia, Mototsugu Muramaki, Yi Xia, Eliana Beraldi, Hideaki Miyake, Amina Zoubeidi, Michael Cox, and Martin Gleave Joseph IschiaJoseph Ischia More articles by this author , Mototsugu MuramakiMototsugu Muramaki More articles by this author , Yi XiaYi Xia More articles by this author , Eliana BeraldiEliana Beraldi More articles by this author , Hideaki MiyakeHideaki Miyake More articles by this author , Amina ZoubeidiAmina Zoubeidi More articles by this author , Michael CoxMichael Cox More articles by this author , and Martin GleaveMartin Gleave More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1618AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Castration and the next generation androgen receptor (AR) antagonist enzalutamide have been shown to improve survival in men with advanced prostate cancer. However, resistance will inevitably develop via a multitude of possible mechanisms which include insulin-like growth factor (IGF) signaling. Targeting insulin-like growth factor-binding protein (IGFBP) -2 and IGFBP-5 using a novel bispecific antisense oligodeoxynucleotide (ASO), designated OGX-225, presents as one strategy to treat castration and enzalutamide-resistant prostate cancer. Methods Effects of OGX-225 on IGFBP-2 and IGFBP-5 expression levels, cell growth, and apoptosis were evaluated in human castrate sensitive (LNCaP), castrate resistant (PC-3, 22RV1 and V16D), and enzalutamide-resistant (MR42D and MR49F) prostate cancer cell lines in vitro. The effect of OGX-225 on LNCaP and PC-3 xenograft growth was also evaluated. Results Whole transcriptome analysis demonstrated that mRNA for IGFBP-2 is overexpressed (4 fold) in castrate resistant prostate cancer cell lines; and that the expression of IGFBP-5 increases over 300 fold in enzalutamide-resistant MR42D prostate cancer cells compared to LNCaP parental cells. OGX-225 induced potent dose-dependent, sequence-specific knockdown of IGFBP-2 in LNCaP, 22Rv1, MR42D, and MR49F, and IGFBP-5 expression in PC3 cells. This treatment decreased cell viability by over 50% in all cell lines through induction of a strong apoptotic response. Compared to control ASO, OGX-225 significantly suppressed castrate-resistant progression of LNCaP xenografts as measured by delayed tumor growth and serum prostate-specific antigen levels. OGX-225 also inhibited growth of androgen-independent PC-3 xenografts. Pharmacodynamic activity of OGX-225 in vivo was demonstrated through significant down-regulation of IGFBP-2 and IGFBP-5 mRNA levels in the LNCaP and PC3 xenografts, respectively. Conclusions This study reports the first preclinical proof-of-principle data that a novel bispecific inhibitor of IGFBP-2 and IGFBP-5, OGX-225, delays prostate cancer progression and displays specific anti-cancer activity in enzalutamide-resistant prostate cancer cell lines. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e582-e583 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Joseph Ischia More articles by this author Mototsugu Muramaki More articles by this author Yi Xia More articles by this author Eliana Beraldi More articles by this author Hideaki Miyake More articles by this author Amina Zoubeidi More articles by this author Michael Cox More articles by this author Martin Gleave More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2152667734 created "2016-06-24" @default.
• W2152667734 creator A5038938817 @default.
• W2152667734 creator A5041954417 @default.
• W2152667734 creator A5062125605 @default.
• W2152667734 creator A5062470491 @default.
• W2152667734 creator A5072032572 @default.
• W2152667734 creator A5081653545 @default.
• W2152667734 creator A5087096448 @default.
• W2152667734 creator A5089530310 @default.
• W2152667734 date "2014-04-01" @default.
• W2152667734 modified "2023-10-16" @default.
• W2152667734 title "MP52-08 TARGETING IGFBP-2 AND IGFBP-5 IN CASTRATION AND ENZALUTAMIDE RESISTANT PROSTATE CANCER" @default.
• W2152667734 doi "https://doi.org/10.1016/j.juro.2014.02.1618" @default.
• W2152667734 hasPublicationYear "2014" @default.
• W2152667734 type Work @default.
• W2152667734 sameAs 2152667734 @default.
• W2152667734 citedByCount "0" @default.
• W2152667734 crossrefType "journal-article" @default.
• W2152667734 hasAuthorship W2152667734A5038938817 @default.
• W2152667734 hasAuthorship W2152667734A5041954417 @default.
• W2152667734 hasAuthorship W2152667734A5062125605 @default.
• W2152667734 hasAuthorship W2152667734A5062470491 @default.
• W2152667734 hasAuthorship W2152667734A5072032572 @default.
• W2152667734 hasAuthorship W2152667734A5081653545 @default.
• W2152667734 hasAuthorship W2152667734A5087096448 @default.
• W2152667734 hasAuthorship W2152667734A5089530310 @default.
• W2152667734 hasConcept C121608353 @default.
• W2152667734 hasConcept C126322002 @default.
• W2152667734 hasConcept C143998085 @default.
• W2152667734 hasConcept C2776235491 @default.
• W2152667734 hasConcept C2776551883 @default.
• W2152667734 hasConcept C2777899217 @default.
• W2152667734 hasConcept C2779723316 @default.
• W2152667734 hasConcept C2780192828 @default.
• W2152667734 hasConcept C502942594 @default.
• W2152667734 hasConcept C61367390 @default.
• W2152667734 hasConcept C71924100 @default.
• W2152667734 hasConceptScore W2152667734C121608353 @default.
• W2152667734 hasConceptScore W2152667734C126322002 @default.
• W2152667734 hasConceptScore W2152667734C143998085 @default.
• W2152667734 hasConceptScore W2152667734C2776235491 @default.
• W2152667734 hasConceptScore W2152667734C2776551883 @default.
• W2152667734 hasConceptScore W2152667734C2777899217 @default.
• W2152667734 hasConceptScore W2152667734C2779723316 @default.
• W2152667734 hasConceptScore W2152667734C2780192828 @default.
• W2152667734 hasConceptScore W2152667734C502942594 @default.
• W2152667734 hasConceptScore W2152667734C61367390 @default.
• W2152667734 hasConceptScore W2152667734C71924100 @default.
• W2152667734 hasIssue "4S" @default.
• W2152667734 hasLocation W21526677341 @default.
• W2152667734 hasOpenAccess W2152667734 @default.
• W2152667734 hasPrimaryLocation W21526677341 @default.
• W2152667734 hasRelatedWork W1915769685 @default.
• W2152667734 hasRelatedWork W2324289718 @default.
• W2152667734 hasRelatedWork W2479374634 @default.
• W2152667734 hasRelatedWork W2503901337 @default.
• W2152667734 hasRelatedWork W2931472946 @default.
• W2152667734 hasRelatedWork W2948523439 @default.
• W2152667734 hasRelatedWork W2954288014 @default.
• W2152667734 hasRelatedWork W2977285099 @default.
• W2152667734 hasRelatedWork W3198382015 @default.
• W2152667734 hasRelatedWork W4282974758 @default.
• W2152667734 hasVolume "191" @default.
• W2152667734 isParatext "false" @default.
• W2152667734 isRetracted "false" @default.
• W2152667734 magId "2152667734" @default.
• W2152667734 workType "article" @default.